GlassScriptPhysician profile
Suchitra Pilli
NPI 1750649844
$37,926.86
in general payments reported to CMS, 2019-2025
40 companies · $7,124 in 2025
The $7,124 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,470 · 2020: $334 · 2021: $245 · 2022: $420 · 2023: $23K · 2024: $2,973 · 2025: $7,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $16K · Consulting Fee: $9,833 · Food and Beverage: $5,608 · Travel and Lodging: $1,407 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $16,000.00 |
| Consulting Fee | $9,832.71 |
| Food and Beverage | $5,608.11 |
| Travel and Lodging | $1,406.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $611.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $22,467.61 | 2019-2025 | Da Vinci Surgical System, Ion |
| Ambu INC. | $10,272.58 | 2023-2024 | |
| Pulmonx Corporation | $1,183.30 | 2021-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Astrazeneca Pharmaceuticals LP | $910.82 | 2019-2025 | Fasenra, Airsupra, Symbicort |
| Noah Medical Corporation | $322.75 | 2025 | Galaxy |
| Galvanize Therapeutics, INC | $321.87 | 2024-2025 | Aliya System |
| Grifols USA, LLC | $236.66 | 2020-2023 | Prolastin-C Liquid |
| Boston Scientific Corporation | $223.08 | 2019-2025 | Wallflex Duodenal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.63 | 2019-2023 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $164.17 | 2023-2024 | Libtayo, Dupixent |
| Steris Corporation | $157.70 | 2025 | |
| Siemens Medical Solutions USA, INC. | $140.85 | 2024-2025 | Cios Spin |
| Novo Nordisk INC | $125.00 | 2025 | Ozempic |
| Becton, Dickinson and Company | $111.00 | 2023-2025 | |
| Genentech USA, INC. | $105.50 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suchitra Pilli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.